Not intended for UK-based media Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, …
source https://finance.yahoo.com/news/data-esmo-2019-merck-kgaa-060000693.html?.tsrc=rss
blaineonline.finance.blog 